Compare Icl Group Ltd (ICL) vs Oruka Therapeutics Inc. Common Stock (ORKA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Icl Group Ltd vs Oruka Therapeutics Inc. Common Stock — how do they compare? Icl Group Ltd trades at $4.99 (market cap $6.47B), while Oruka Therapeutics Inc. Common Stock trades at $75.2 (market cap $5.08B). The key difference: Icl Group Ltd is the larger of the two by market cap, and Icl Group Ltd pays a 4.12% dividend while Oruka Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Icl Group Ltd for 56 Days and Oruka Therapeutics Inc. Common Stock for 0 Days on average.
| ICL | ORKA | |
|---|---|---|
Market Cap | $6.47B | $5.08B |
Volume | 1,473,067 | 685,276 |
Sector | Basic Materials | Health |
52-Week High | $6.80 | $113.08 |
52-Week Low | $4.80 | $26.19 |
Typical Hold Time | 56 Days | 0 Days |
Enterprise Value | $9.10B | $4.21B |
Dividend Yield | 4.12% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ICL trades at $4.98, up 0.81% today, with a bearish technical signal from moving averages. The company reported Q2 2026 EPS of $0.12, beating expectations, but revenue and net income have declined from 2022 peaks. Valuation ratios appear reasonable with P/E of 20.75 and P/B of 1.05. All four covering analysts maintain Hold ratings with a $6.08 consensus target, suggesting 22% upside potential.
The outlook remains cautious due to industry headwinds and declining profitability, though the dividend yield provides some support. Key risks include fertilizer market volatility and execution of the cost-transformation program. The stock offers value but requires monitoring of operational improvements and market conditions for sustained recovery.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Icl Group Ltd
ICL Group Ltd is a manufacturer of products based on minerals. The firm is comprised of four segments: phosphate solutions, potash, industrial products, and innovative agriculture solutions (IAS). These segments all contribute to the company's development of agriculture, food, and engineered material products and services. The company mines and manufactures potash and phosphates to be used as ingredients in fertilizers and serve as a component in the pharmaceutical and food additives industries. It is also engaged in industrial additives and materials, including flame retardants, phosphate salts, specialty phosphate blends, purified phosphoric acid, electronic-grade specialty phosphoric acids. Its geographical segments are Europe, Asia, North & South America, and the Rest of the world.
Read more on ICL →About Oruka Therapeutics Inc. Common Stock
Oruka Therapeutics, Inc. is a clinical-stage biotechnology company developing extended half-life monoclonal antibodies for plaque psoriasis, psoriatic arthritis, and related dermatologic conditions, with lead candidates ORKA-001 and ORKA-002 in clinical trials.
Read more on ORKA →
